Medtronic plc, of Dublin, highlighted results of a study that demonstrated a reduction in health care utilization and cost for cancer pain patients using targeted drug delivery (TDD) and conventional medical management (CMM) vs. CMM alone. TDD was delivered by the Medtronic Synchromed II infusion system, which is an implantable pump that delivers medication directly to the fluid around the spinal cord.